Retatrutide

Scientific Overview, Mechanism, Clinical Use and Evidence

Scientific Overview

Retatrutide is a novel synthetic peptide designed as a triple agonist of the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This multimodal incretin-based approach was developed to enhance weight loss and metabolic improvement beyond what is achievable with dual or single incretin agonists.

Mechanism of Action

Retatrutide simultaneously activates GLP-1, GIP, and glucagon receptors:

• GLP-1 and GIP receptor activation promotes glucose-dependent insulin secretion and appetite suppression
• Delayed gastric emptying contributes to reduced caloric intake
• Glucagon receptor activation increases energy expenditure and lipolysis
• Combined effect results in potent reductions in body weight

Biological and Clinical Effects

Clinical trials demonstrate substantial reductions in body weight, body fat percentage, and cardiometabolic risk factors. Improvements in insulin sensitivity, lipid profiles, and hepatic steatosis markers have also been reported. Weight loss observed with retatrutide exceeds that reported for currently approved GLP-1 receptor agonists in comparable study durations.

Time of Use / Treatment Duration

Clinical trials typically assess retatrutide over 24 to 48 weeks, with progressive and sustained weight loss observed throughout treatment. Long-term safety and maintenance strategies remain under investigation.

Safety, Tolerability, and Precautions

The most common adverse events are gastrointestinal, including nausea, vomiting, diarrhea, and constipation, particularly during dose escalation. Transient increases in heart rate have been observed. Hypoglycemia risk is low when not combined with insulin or insulin secretagogues. Due to limited long-term data, retatrutide should be avoided in pregnancy, breastfeeding, patients with a history of medullary thyroid carcinoma or MEN2, and individuals with severe gastrointestinal disease.

Detailed References

Jastreboff AM et al. (2023). Triple–hormone–receptor agonist retatrutide for obesity — A phase 2 trial. New England Journal of Medicine, 389, 514–526.

Coskun T et al. (2022). Discovery and preclinical characterization of a triagonist targeting GLP-1, GIP, and glucagon receptors. Cell Metabolism, 34(6), 915–928.

Kaplan LM et al. (2023). Metabolic effects of triple incretin receptor agonism in obesity. Nature Reviews Endocrinology, 19, 543–555.

Müller TD et al. (2022). Anti-obesity drug discovery: Advances in multi-agonist peptide therapeutics. Nature Reviews Drug Discovery, 21, 201–223.

Posology (Clinical Practice–Oriented)

Investigational dosing regimens initiate at low weekly subcutaneous doses with gradual titration.

Clinical studies have evaluated doses ranging from 1 mg to 12 mg administered once weekly. Dose escalation is performed cautiously to improve gastrointestinal tolerability.

Retatrutide is investigational; all use must be physician-supervised.

Clinical Practice Framing

Retatrutide is an investigational peptide with encouraging clinical data in obesity and metabolic disease. As a triple incretin agonist, it represents one of the most potent metabolic peptide approaches currently in clinical development.

The peptides described in this material are intended strictly for research purposes only. They are not approved for human or veterinary use, clinical application, diagnosis, treatment, or prevention of any disease.

Any research involving these compounds must be conducted in compliance with applicable laws and regulations in the country where the research is performed, including prior approval by a duly constituted Ethics Committee or Institutional Review Board (IRB), where required.

RegenPept acts solely as a supplier of research-grade materials and assumes no responsibility or liability for the design, conduct, regulatory compliance, interpretation, or outcomes of any research involving these products.

Any dosage, administration protocols, or related information contained in this material are derived from publicly available scientific literature and are provided strictly for informational purposes. Such information does not constitute medical advice, therapeutic recommendation, or endorsement of any specific use by RegenPept.